Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index; 161 of the 331 sources its claims cite were checked for support.

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan

Open access
Tuccinardi, Dario, Masi, Davide, Watanabe, Mikiko, Zanghi Buffi, Valeria, De Domenico, Francesco, Berti, Sabrina, Cipriani, Valentina, Manco, Melania, Manfrini, Silvia, Pagotto, Uberto · 2025 · Journal of Endocrinological Investigation

Abstract

OBJECTIVE: Obesity is a biologically complex and heterogeneous disease that requires individualized, phenotype- and complication-oriented therapeutic strategies. The introduction of advanced pharmacotherapies, including GLP-1 receptor agonists (GLP-1 RA), dual Glucose-dependent Insulinotropic Polypeptide/Glucagon-like Peptide-1 (GIP/GLP-1) agonists, and emerging triple agonists, has facilitated a shift from weight-centric goals to precision-based obesity care. This review provides a clinical framework for pharmacologic treatment, organized by phenotype, obesity-related complications, age, and behavioral traits. DESIGN: Narrative review of randomized trials, meta-analyses, real-world evidence, and international guidelines through May 2025. Evidence was synthesized across key obesity phenotypes, cardiometabolic, hepatic, renal, mechanical, behavioral, and stratified by life stage, including pediatric, reproductive-age, and older adults, with attention to safety, cost-effectiveness, and special populations. RESULTS: In established Atherosclerotic Cardiovascular Disease, semaglutide significantly reduces major adverse cardiovascular events. Tirzepatide offers cardiometabolic benefits for high-risk people without overt disease. Both agents improve symptoms and function in Heart Failure with Preserved Ejection Fraction, irrespective of glycemia or weight loss. In Chronic Kidney Disease, they decrease albuminuria and eGFR decline. In Metabolic Dysfunction-Associated Steatotic Liver Disease, GLP-1 RAs and GIP/GLP-1 RAs demonstrate marked histological improvements. Mechanical complications such as osteoarthritis and sleep apnea are improved by anti-obesity medications-induced weight loss. GLP-1 RAs and naltrexone/bupropion prove effective against binge and emotional eating. In youths, liraglutide and semaglutide are both approved and effective. Liraglutide and orlistat preserve lean mass alongside resistance training and adequate protein intake in older and sarcopenic people. CONCLUSIONS: An anti-obesity treatment framework focused on both phenotype and complication burden improves the personalization of obesity care and supports clinical decision-making throughout a person’s lifespan.

Overview

CoChat Summary

TL;DR

This is a narrative review that proposes a phenotype- and complication-guided framework for choosing anti-obesity medications and bariatric surgery across the lifespan. It argues that obesity pharmacotherapy should be matched to comorbidities, behavior, age, and cost rather than BMI alone.

Key findings

  • The review synthesizes 200 studies after screening 1,296 titles/abstracts and reviewing 212 full texts; no quantitative meta-analysis was performed.
  • In established ASCVD, semaglutide 2.4 mg once weekly reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90) and all-cause mortality by 19% in people with obesity and established ASCVD without diabetes; in HFpEF, semaglutide improved KCCQ-CSS by +7.8 points and 6MWD by +20.3 m.
  • In prediabetes, tirzepatide 15 mg once weekly produced 22.5% mean weight loss and a 94% risk reduction in diabetes progression over 72 weeks; in a separate trial, diabetes incidence was 1.3% vs 13.3% with placebo (HR 0.07).
  • In MASH, semaglutide and tirzepatide showed major histologic benefits: semaglutide achieved 59% vs 17% MASH resolution in a phase 2 trial and 62.9% vs 34.3% steatohepatitis resolution without worsening fibrosis in ESSENCE; tirzepatide achieved 44%/56%/62% MASH resolution at 5/10/15 mg vs 10% placebo.

Methods

  • Narrative review led by a multidisciplinary panel of endocrinologists, pediatricians, registered dietitians, and obesity medicine specialists.
  • Literature searched from January 1998 to May 2025 across PubMed/MEDLINE, Scopus, Cochrane CENTRAL, ClinicalTrials.gov, regulatory sources (EMA/FDA), and manual journal searches; included RCTs, meta-analyses, observational studies, guidelines, and expert consensus documents in English.
  • Evidence was organized by phenotype, complication, age/life stage, safety, and cost-effectiveness; recommendations were qualitatively labeled “should be preferred,” “may be considered,” or “not recommended,” with no quantitative meta-analysis.

Limitations

  • The paper states that direct head-to-head trials between anti-obesity medications are lacking, limiting comparative conclusions.
  • It states that behavioral and psychosocial phenotypes are underrepresented in major trials, which constrains generalizability.
  • It states that cost-effectiveness models are highly context-specific and may not extrapolate across healthcare systems.
  • Evident from the text: this is a narrative review rather than a de novo clinical trial, so conclusions depend on the quality and heterogeneity of the underlying studies (this is evident from the design and synthesis approach).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40618-025-02700-7

Cites

200 of 201 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 A Phenotype-Guided Framework for Obesity Pharmacotherapy.This figure presents a structured, phenotype-based model for pharmacologic obesity treatment, in which each column corresponds to a major complication domain of obesity. Within each column, content is organized in a hierarchical sequence: first, the clinical complication (e.g., type 2 diabetes, ASCVD, MASLD, CKD, OSA, OA, eating disorders); second, the diagnostic definitions and inclusion criteria used in pivotal trials that demonstrated efficacy of anti-obesity medications (AOMs) in that phenotype; third, the pharmacologic agents tested in those populations, ordered from top to bottom according to the strength of recommendation, beginning with agents that should be prioritized based on evidence and magnitude of effect. Where applicable, the figure also outlines referral to bariatric surgery when pharmacologic strategies are insufficient, followed by the option of re-introducing AOMs after surgical failure or weight regain. This sequence underscores the need for dynamic treatment strategies based on response rather than rigid therapeutic escalation. Rather than endorsing a fixed stepwise progression from lifestyle to drugs to surgery, the framework supports a personalized approach integrating patient phenotype, complication burden, treatment goals, and shared decision-making. The model reflects a shift toward complication-driven precision medicine in obesity, emphasizing early, targeted intervention and long-term outcome optimization. Abbreviations: AOMs, Anti-Obesity Medications; ASCVD, Atherosclerotic Cardiovascular Disease; HFpEF, Heart Failure with Preserved Ejection Fraction; CKD, Chronic Kidney Disease; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease; MASH, Metabolic Dysfunction-Associated Steatohepatitis; T2DM, Type 2 Diabetes Mellitus; T1DM, Type 1 Diabetes Mellitus; PCOS, Polycystic Ovary Syndrome; OSA, Obstructive Sleep Apnea; OA, Osteoarthritis; OWCMC, Obesity Without Clinically Manifest Complications; EBD, Eating Behavior Disorder; AHI, Apnea–Hypopnea Index; CPAP, Continuous Positive Airway Pressure; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; eGFR, Estimated Glomerular Filtration Rate; ACR, Albumin-to-Creatinine Ratio; NYHA, New York Heart Association; LVEF, Left Ventricular Ejection Fraction; QALY, Quality-Adjusted Life Year; BS, Bariatric Surgery; GI, Gastrointestinal
Fig. 1 A Phenotype-Guided Framework for Obesity Pharmacotherapy.This figure presents a structured, phenotype-based model for pharmacologic obesity treatment, in which each column corresponds to a major complication domain of obesity. Within each column, content is organized in a hierarchical sequence: first, the clinical complication (e.g., type 2 diabetes, ASCVD, MASLD, CKD, OSA, OA, eating disorders); second, the diagnostic definitions and inclusion criteria used in pivotal trials that demonstrated efficacy of anti-obesity medications (AOMs) in that phenotype; third, the pharmacologic agents tested in those populations, ordered from top to bottom according to the strength of recommendation, beginning with agents that should be prioritized based on evidence and magnitude of effect. Where applicable, the figure also outlines referral to bariatric surgery when pharmacologic strategies are insufficient, followed by the option of re-introducing AOMs after surgical failure or weight regain. This sequence underscores the need for dynamic treatment strategies based on response rather than rigid therapeutic escalation. Rather than endorsing a fixed stepwise progression from lifestyle to drugs to surgery, the framework supports a personalized approach integrating patient phenotype, complication burden, treatment goals, and shared decision-making. The model reflects a shift toward complication-driven precision medicine in obesity, emphasizing early, targeted intervention and long-term outcome optimization. Abbreviations: AOMs, Anti-Obesity Medications; ASCVD, Atherosclerotic Cardiovascular Disease; HFpEF, Heart Failure with Preserved Ejection Fraction; CKD, Chronic Kidney Disease; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease; MASH, Metabolic Dysfunction-Associated Steatohepatitis; T2DM, Type 2 Diabetes Mellitus; T1DM, Type 1 Diabetes Mellitus; PCOS, Polycystic Ovary Syndrome; OSA, Obstructive Sleep Apnea; OA, Osteoarthritis; OWCMC, Obesity Without Clinically Manifest Complications; EBD, Eating Behavior Disorder; AHI, Apnea–Hypopnea Index; CPAP, Continuous Positive Airway Pressure; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; eGFR, Estimated Glomerular Filtration Rate; ACR, Albumin-to-Creatinine Ratio; NYHA, New York Heart Association; LVEF, Left Ventricular Ejection Fraction; QALY, Quality-Adjusted Life Year; BS, Bariatric Surgery; GI, GastrointestinalCC BY · PubMed Central
Fig. 2 Precision Obesity Medicine: Integrating Age, Phenotype, and Pharmacotherapy.This figure illustrates a comprehensive framework for precision obesity care, integrating age-based stratification (upper trajectory), phenotype-driven treatment selection (lower trajectory), and weight loss targets across the lifespan. The top section delineates recommended pharmacologic options according to developmental stage—from infancy (≥ 2 years) to sarcopenic obesity in late adulthood—highlighting specific agents with supporting evidence and safety considerations. The lower section maps obesity-related complications along a phenotypic continuum, spanning metabolic–cardio–renal diseases (e.g., type 2 diabetes, ASCVD, CKD, MASLD/MASH), mechanical complications (e.g., osteoarthritis, OSA), and behavioral phenotypes (e.g., emotional eating), together with target weight loss milestones (5%, 10–20%, > 20%). Each condition is annotated with preferred pharmacologic agents, based on available efficacy and safety data. Agents are color-coded by recommendation grade (green = preferred; yellow = caution or off-label; red = contraindicated). The figure supports individualized, complication-oriented obesity management and underscores the need for phenotype-guided drug selection beyond a weight-centric model. BMI, Body Mass Index; T2DM, Type 2 Diabetes Mellitus; ASCVD, Atherosclerotic Cardiovascular Disease; HFpEF, Heart Failure with Preserved Ejection Fraction; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease; MASH, Metabolic Dysfunction-Associated Steatohepatitis; CKD, Chronic Kidney Disease; PCOS, Polycystic Ovary Syndrome; OSAS, Obstructive Sleep Apnea Syndrome; OA, Osteoarthritis; OWCMC, Obesity Without Clinically Manifest Complications; EBD, Eating Behavior Disorder
Fig. 2 Precision Obesity Medicine: Integrating Age, Phenotype, and Pharmacotherapy.This figure illustrates a comprehensive framework for precision obesity care, integrating age-based stratification (upper trajectory), phenotype-driven treatment selection (lower trajectory), and weight loss targets across the lifespan. The top section delineates recommended pharmacologic options according to developmental stage—from infancy (≥ 2 years) to sarcopenic obesity in late adulthood—highlighting specific agents with supporting evidence and safety considerations. The lower section maps obesity-related complications along a phenotypic continuum, spanning metabolic–cardio–renal diseases (e.g., type 2 diabetes, ASCVD, CKD, MASLD/MASH), mechanical complications (e.g., osteoarthritis, OSA), and behavioral phenotypes (e.g., emotional eating), together with target weight loss milestones (5%, 10–20%, > 20%). Each condition is annotated with preferred pharmacologic agents, based on available efficacy and safety data. Agents are color-coded by recommendation grade (green = preferred; yellow = caution or off-label; red = contraindicated). The figure supports individualized, complication-oriented obesity management and underscores the need for phenotype-guided drug selection beyond a weight-centric model. BMI, Body Mass Index; T2DM, Type 2 Diabetes Mellitus; ASCVD, Atherosclerotic Cardiovascular Disease; HFpEF, Heart Failure with Preserved Ejection Fraction; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease; MASH, Metabolic Dysfunction-Associated Steatohepatitis; CKD, Chronic Kidney Disease; PCOS, Polycystic Ovary Syndrome; OSAS, Obstructive Sleep Apnea Syndrome; OA, Osteoarthritis; OWCMC, Obesity Without Clinically Manifest Complications; EBD, Eating Behavior DisorderCC BY · PubMed Central

Verification

Claims the paper makes

140 Valid · 24 Not valid · 150 Not checked · 63 Own results and interpretations

168 more claims · 72 with their cited sources checked

Create a free account to see all 377 claims and to verify the 27 references still open.

See all claims — free account
  • It may state two separate claims as one. 175
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 43

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 194 references

Research works printed but not linked: 2

  1. Castano GSS (2024) Real-world implications and limitations of GLP-1 prescriptions in adolescents. J Endocr Soc 8(Suppl 1):bae163.1506. https://doi.org/10.1210/jendso/bae163.1506. (PMCID: PMC11454784) · doi:10.1210/jendso/bae163.1506
  2. Website ICER, Accessed June 17, 2025. [Online]. Available: https://icer.org/news-insights/journal-articles/cost-effectiveness-of-oral-semaglutide-added-to-current-antihyperglycemic-treatment-for-type-2-diabetes

Cited by

See all 29

Metadata

Authors
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U.
Affiliations
  • Università Campus Bio-Medico (IT)
  • Sapienza University of Rome (IT)
  • University of Bologna (IT)
  • Campus Bio Medico University Hospital (IT)
  • Bambino Gesù Children's Hospital (IT)
Corresponding author
  • Tuccinardi, Dario
  • Watanabe, Mikiko
Venue
Journal of Endocrinological Investigation
Published
2025-11-10
Volume
48
Issue
12
Pages
2761-2798
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W4416063077
Cited by
29
References
194
Citations by year
2026: 28 · 2025: 1
FWCI
3.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Endocrinological Investigation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
Funders
EUROPEAN UNION (NextGenerationEU, under the Italian Ministry of University and Research (MUR) PRIN 2022 program, Mission 4, Component 1, CUP C53D23006490001.)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
obesity, precision medicine, obesity phenotypes, obesity pharmacotherapy, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, semaglutide, tirzepatide, liraglutide, orlistat, naltrexone/bupropion, cardiometabolic complications, heart failure with preserved ejection fraction, chronic kidney disease, non-alcoholic fatty liver disease, sleep apnea, osteoarthritis, binge eating, emotional eating, childhood obesity, sarcopenia, older adults, weight loss
MeSH terms
Tirzepatide, Semaglutide, Humans, Longevity, Obesity, Phenotype, Anti-Obesity Agents, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. https://app.cochat.ai/papers/10.1007/s40618-025-02700-7
The paper
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025). Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-025-02700-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.